SPPI News and Press, Spectrum Pharmaceuticals Inc. From 12/22/20

FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA submission planned for 2021 Cohort 3 of the ZENITH20 clinical trial, which enrolled first-line NSCLC patients ...

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan to its Board of Directors. Ms. Brennan fills a vacancy left by Ms. Elizabeth Czerepak, who retired from the Board effec...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that three posters highlighting its drug development pipeline would be presented at the upcoming San Antonio Breast Cancer Conference (SABCS) to be he...

Spectrum Pharma is down due to two resolvable issues. If the Rolontis PDUFA issue is resolved, the stock may shoot up. The Poziotinib situation works as a nice backup to the story. For further details see: Spectrum Pharma Is Down But Not Out

Spectrum is a $550m market cap biotech developing 2 drugs that are close to securing FDA approval but are subject to frustrating delays. A PDUFA date for Severe Neutropenia treatment Rolontis has been delayed until the FDA can complete a visit to Spectrum's partner Hanmi's South Korea...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conference...

Image source: The Motley Fool. Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) Q3 2020 Earnings Call Nov 4, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Spectrum Pharmaceuticals Inc (SPPI) Q3 2020 Earnings Call Trans...

Spectrum Pharmaceuticals, Inc. (SPPI) Q3 2020 Earnings Conference Call November 4, 2020 4:30 P.M. ET Company Participants Kurt Gustafson - Chief Financial Officer Joe Turgeon - President and Chief Executive Officer François Lebel - Chief Medical Officer Tom Riga - Chief Operating Officer...

Spectrum Pharmaceuticals (SPPI): Q3 Non-GAAP EPS of -$0.27; GAAP EPS of -$0.37 misses by $0.02.The company ended the quarter with cash, cash equivalents, and marketable securities of $198.3 million.Press Release For further details see: Spectrum Pharmaceuticals EPS misses by $0.02